Design Therapeutics Statistics
Total Valuation
DSGN has a market cap or net worth of $326.31 million. The enterprise value is $111.98 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DSGN has 56.95 million shares outstanding. The number of shares has increased by 0.80% in one year.
| Current Share Class | 56.95M |
| Shares Outstanding | 56.95M |
| Shares Change (YoY) | +0.80% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 15.49% |
| Owned by Institutions (%) | 38.66% |
| Float | 23.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.53 |
| P/TBV Ratio | 1.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 25.13, with a Debt / Equity ratio of 0.01.
| Current Ratio | 25.13 |
| Quick Ratio | 24.88 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.77% and return on invested capital (ROIC) is -19.56%.
| Return on Equity (ROE) | -26.77% |
| Return on Assets (ROA) | -19.02% |
| Return on Invested Capital (ROIC) | -19.56% |
| Return on Capital Employed (ROCE) | -34.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.18M |
| Employee Count | 54 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.24% in the last 52 weeks. The beta is 1.69, so DSGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.69 |
| 52-Week Price Change | +1.24% |
| 50-Day Moving Average | 6.03 |
| 200-Day Moving Average | 4.63 |
| Relative Strength Index (RSI) | 44.37 |
| Average Volume (20 Days) | 200,290 |
Short Selling Information
The latest short interest is 3.55 million, so 6.23% of the outstanding shares have been sold short.
| Short Interest | 3.55M |
| Short Previous Month | 3.68M |
| Short % of Shares Out | 6.23% |
| Short % of Float | 15.22% |
| Short Ratio (days to cover) | 18.76 |
Income Statement
| Revenue | n/a |
| Gross Profit | -44.53M |
| Operating Income | -74.93M |
| Pretax Income | -63.49M |
| Net Income | -63.49M |
| EBITDA | -74.31M |
| EBIT | -74.93M |
| Earnings Per Share (EPS) | -$1.12 |
Full Income StatementBalance Sheet
The company has $216.28 million in cash and $1.95 million in debt, giving a net cash position of $214.33 million or $3.76 per share.
| Cash & Cash Equivalents | 216.28M |
| Total Debt | 1.95M |
| Net Cash | 214.33M |
| Net Cash Per Share | $3.76 |
| Equity (Book Value) | 213.04M |
| Book Value Per Share | 3.74 |
| Working Capital | 211.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$50.64 million and capital expenditures -$143,000, giving a free cash flow of -$50.78 million.
| Operating Cash Flow | -50.64M |
| Capital Expenditures | -143,000 |
| Free Cash Flow | -50.78M |
| FCF Per Share | -$0.89 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
